Suppr超能文献

开胸术后布比卡因肋间镇痛:一项对照研究的无效结果及药代动力学

Interpleural analgesia with bupivacaine following thoracotomy: ineffective results of a controlled study and pharmacokinetics.

作者信息

Elman A, Debaene B, Magny-Metrot C, Murciano G

机构信息

Department of Anesthesiology, Hôpital Beaujon, Clichy, France.

出版信息

J Clin Anesth. 1993 Mar-Apr;5(2):118-21. doi: 10.1016/0952-8180(93)90138-5.

Abstract

STUDY OBJECTIVE

To evaluate intrapleural analgesia with bupivacaine following partial pulmonary resection and to determine pharmacokinetic parameters of bupivacaine with epinephrine.

DESIGN

Prospective, randomized study.

SETTING

Thoracic surgical clinic of a university-affiliated general hospital.

PATIENTS

Eighteen consecutive patients (13 men, 5 women) scheduled for pulmonary surgery by posterolateral thoracotomy.

INTERVENTIONS

Bupivacaine was administered through an intrapleural catheter as a bolus dose of either 40 ml of 0.25% bupivacaine with epinephrine (0.5 mg per 100 ml of solution) (n = 10) or 20 ml of 0.5% bupivacaine with epinephrine (0.5 mg per 100 ml of solution) (n = 8) up to three times daily for a maximum time of 4 days.

MEASUREMENTS AND MAIN RESULTS

Subjective evaluation of pain was performed using the visual analog scale (VAS) before and after each injection by response to spontaneous pain, coughing, deep breathing, and incision palpation. Maximum peak concentration (C Max) and maximum time to reach the peak concentration (T Max) were assessed after the first and last injections. Although VAS pain score decreased significantly, pain relief was not sufficient. C Max and T Max after the first and last injections were not significantly different between the two groups. In each group, C Max after the last injection was significantly higher than after the first injection.

CONCLUSIONS

Intrapleural analgesia conducted with 40 ml of 0.25% bupivacaine with epinephrine or 20 ml of 0.5% bupivacaine with epinephrine was insufficient for pain, despite high plasma bupivacaine concentration.

摘要

研究目的

评估布比卡因在部分肺切除术后的胸膜内镇痛效果,并确定布比卡因与肾上腺素联用的药代动力学参数。

设计

前瞻性随机研究。

地点

大学附属医院胸外科诊所。

患者

18例连续行后外侧开胸肺手术的患者(男13例,女5例)。

干预措施

通过胸膜内导管给予布比卡因,作为单次推注剂量,40ml含肾上腺素(每100ml溶液含0.5mg)的0.25%布比卡因(n = 10)或20ml含肾上腺素(每100ml溶液含0.5mg)的0.5%布比卡因(n = 8),每日最多3次,最长持续4天。

测量指标及主要结果

每次注射前后,通过对自发痛、咳嗽、深呼吸和切口触诊的反应,使用视觉模拟评分法(VAS)进行疼痛的主观评估。在首次和末次注射后评估最大峰值浓度(C Max)和达到峰值浓度的最长时间(T Max)。虽然VAS疼痛评分显著降低,但疼痛缓解仍不充分。两组首次和末次注射后的C Max和T Max无显著差异。每组中,末次注射后的C Max显著高于首次注射后的C Max。

结论

尽管血浆布比卡因浓度较高,但40ml含肾上腺素的0.25%布比卡因或20ml含肾上腺素的0.5%布比卡因进行胸膜内镇痛对疼痛的缓解并不充分。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验